Published in Cancer Weekly, November 5th, 2002
"The drug is designed to kill the cancer cells and to stop tumor growth by using what is called the p53 suppressor gene," said Missak Haigentz, MD, an oncologist and principal investigator for the study at Montefiore. The p53 gene, when mutated, is frequently associated with the unregulated growth of cancer cells.
Head and neck cancers account for approximately...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.